NCT06880523 - STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

December 31, 2028

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

STRIDE (durvalumab + tremelimumab)

As first treatment

DRUG

Durvalumab

monotherapy every 4 weeks

DRUG

Lenvatinib

Daily

Trial Locations (4)

Arthur J.E. Child Comprehensive Cancer Centre, Calgary

BCCA - Vancouver, Vancouver

Waterloo Regional Health Network (WRHN), Kitchener

University Health Network, Toronto